Profitability will be announced in January for the first time.
トレード稼働中:
Graham Mullis, CEO of Novacyt Group, said:
"Overall, I am satisfied with the operational progress achieved by the Group, with a solid order book, the progress of the integration of the Omega ID business and the new molecular tests benefiting from CE marking launched at the end of the year. last year, as well as new CE marked molecular products planned for 2019. We are confident that the financial performance will improve significantly in 2019, with the finalization of the sale of the NOVAprep® activity as well as that of the Clinical Lab. We expect that, based on continuing operations, the Company will achieve increased EBITDA profitability in 2019. We remain committed to our three strategic pillars of organic growth, external growth and research&Development growth."
"Overall, I am satisfied with the operational progress achieved by the Group, with a solid order book, the progress of the integration of the Omega ID business and the new molecular tests benefiting from CE marking launched at the end of the year. last year, as well as new CE marked molecular products planned for 2019. We are confident that the financial performance will improve significantly in 2019, with the finalization of the sale of the NOVAprep® activity as well as that of the Clinical Lab. We expect that, based on continuing operations, the Company will achieve increased EBITDA profitability in 2019. We remain committed to our three strategic pillars of organic growth, external growth and research&Development growth."
